Clinical & Pharmaceutical Solutions through Analysis USA (CPSA USA 2020)
Pre-Conference Workshop – Microsampling
Sponsored by New Objective
Kevin Bateman, Merck
“The sharing part is important, it motivates others to do the same” – Kevin Bateman, Merck
The microsampling community continues to improve technologies and solutions for the patient, while working towards understanding human biology. During Kevin’s CPSA Everyday, Microsampling edition, he describes a Vison that is dedicated to motivating others to engage in microsampling – in a collaborative way. While working through the complexity of iterative loops for development of technology to solutions (from a perceived failure, to understanding, to improving the science or process) we can work together with each other’s expertise, for the patient. Each human is different, and such: Why can’t each human be their own control? Starting from a heal prick at birth, can we simply have more data points? Kevin discusses a Vision that also speaks towards patient adherence and regulatory aspects for implementing micosampling solutions. In the end, improving healthcare is not a competition, it is actually a team sport.
7th Annual Brasilian Symposium on Clinical & Pharmaceutical Solutions through Analysis (CPSA BRASIL 2020)
Program Chair – CPSA Brazil 2020 Carlos Kiffer, MD, Ph.D. from Escola Paulista de Medicina / Universidade Federal de São Paulo
“We’re responsible for ourselves as much as we are responsible for our communities.”
“(What COVID-19 brought us) A chance of observing a large number of patients over a small period of time. You start to see patterns.”
“I wish everyone could take care of each other.”
Diseases are complex, and the COVID-19 pandemic presents with several manifestations. Working in infectious disease for over 30 years, Carlos has observed 100’s to 1000’s of patients and works with friends and colleagues to identify patterns related to these different manifestations. They work together to make sense of these patterns through observations of patients in the hospitals, as well as using metabolomics, proteomics, and genetics to measure molecular differences in manifestations. The global pandemic will bring changes to certain approaches used for understanding infectious disease, and Carlos passionately works with community to bring relevant knowledge to design clinical scoring systems to define the spectrum of COVID-19 manifestations.
